The Global Urokinase for Injection Market size is growing at a CAGR of 6.8% during the forecast period 2021-2030.

Urokinase for Injection Market Overview:

Urokinase is a thrombolytic drug, often called a clot-busting drug. Urokinase is a plasminogen activator, a serine protease present in humans and animals. It helps the body produce a substance that dissolves unwanted blood clots, especially in the lungs. Infuse it slowly into a vein by the intravenous route over 12 hours using a continuous infusion pump.

Urokinase increases the risk of severe or life-threatening bleeding. Urokinase was previously used in the healthcare market globally but is now a monopoly. Only one type of thrombolytic drug called tissue plasminogen activator, or TPA, is currently used in clinics and hospitals to dissolve blood clots.

Urokinase for Injection market size estimates and forecasts are provided in terms of sales volume (K units) and revenue (million USD), with historical and forecast data for the period 2017 to 2030, with 2022 being considered as the base year. This report segments the global Urokinase for Injection market in detail. Regional market sizes related to products by type, by application, and by player are also delivered. In estimating the size of the market, we took into account the impact of COVID-19 and other global crisis.

The global Urokinase for Injection market is the professional and accurate study of various business perspectives such as major key players, key geographies, divers, restraints, opportunities, and challenges. This global research report has been aggregated on the basis of various market segments and sub-segments associated with the global market.

Industry News and Key Developments

• In 2018, Microbix Biosystem Inc., a biologics product manufacturer, entered into an agreement with Toreya Partners LLC for re-launch of kinlytics (urokinase) a clot busting drug in the U.S. market.
• In 2019 Syner Medica LTD received approval for marketing of Syner-kinase (urokinase) in the UK by European Medical Agency.
• In March 2018, Microbix Biosystems Inc., a Canadian biotechnology company commercializing novel technologies, and Cadila Healthcare Ltd. (Zydus Cadila) said that they have signed a Letter of Intent (LoI) to market the thrombolytic drug urokinase in the North American market.

Top Key Players include in the Urokinase for Injection Market are
Jiangsu Aidea Pharmaceutical Co Ltd, Jiangxi Haoran Bio-Pharma Co., Ltd, Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, Microbix Biosystems Inc, Syner Medica LTD, ImaRx Therapeutics, Inc, and Wilex AG and others.

The Urokinase for Injection market research report is categorized based on type, applications and region.

On the Basis of Type:

• Urokinase Powder
• Urokinase Solution

On the Basis of Application:

• Hospital
• Clinic

On the Basis of Region:

Geographically, the global Urokinase for Injection market has been analyzed in various regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, Europe, and India. The global Urokinase for Injection region is dominating this market in the upcoming future.

The North American urokinase market for injection is projected to grow at a moderate rate over the forecast period. The growth in this region can be attributed to the increasing number of patients suffering from acute coronary syndrome with chest pain or discomfort due to atherosclerosis which would require surgery such as angioplasty with stent insertion or bypass surgery. The key players operating in the Latin American market are Merck, Sanofi, and Pfizer. Urokinase solution is used for dissolving blood clots to treat heart attacks and deep vein thrombosis while urokinase powder can be administered through an intravenous drip or intra-arterial injection. Europe is a mature market for urokinase injection. The market in this region consists of large and medium-sized enterprises, primarily operating on the basis of long-term contracts with hospitals or clinic organizations. These companies correspondingly have more than one supplier from which they can buy their supply of urokinase powder or solution. The Asia Pacific is expected to be one of the fastest-growing markets for urokinase in injection during the forecast period. The growth drivers are continuous innovation, increase in hospital beds and rise in awareness among consumers about medication safety leading to increased demand for generic drugs.

Further the regions are divided into countries as follows

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Urokinase for Injection Market report scope

The major key questions addressed through this innovative research report:

What are the major challenges in front of the global Urokinase for Injection market?

Who are the key vendors of the global Urokinase for Injection market?

What are the leading key industries of the global Urokinase for Injection market?

Which factors are responsible for driving the global Urokinase for Injection market?

What are the key outcomes of SWOT and Porter’s five analysis?

What are the major key strategies for enhancing global opportunities?

What are the different effective sales patterns?

What will be the global market size in the forecast period?

Any special requirements about this report, please let us know and we can provide custom report.